CALGARY, Alberta, Nov. 29, 2019 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, announces the appointment of Mr. Thomas Smeenk, BA, to […]
Author: Ken Dropiewski
Novoheart Provides Corporate Update
VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced today that Joseph Leung resigned as Chief Financial Officer and Corporate Secretary of the Company effective immediately. Ronald Li, Chief Executive Officer, stated, “On behalf of Novoheart, I would […]
CARMAT Appoints Alexandre Eleonore as Director of Manufacturing
PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announced the appointment of Mr Alexandre Eleonore as Director of Manufacturing. Alexandre Eleonore is a […]
One millionth procedure carried out on Philips Azurion advanced image-guided therapy platform
November 27, 2019 Industry-leading platform combines clinical excellence and workflow innovation, helping clinicians and hospitals to deliver outstanding patient care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the one millionth procedure on its flagship Azurion image-guided therapy platform. Since its introduction […]
Medicure Reports Financial Results for Quarter Ended September 30, 2019
WINNIPEG, Nov. 26, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, today reported its results from operations for the quarter ended September 30, 2019. Quarter Ended September 30, 2019 Highlights: Recorded net revenue from the sale of AGGRASTAT® (tirofiban hydrochloride) of $5.3 million during the quarter ended September 30, 2019 compared to $7.0 million for the […]
HeartGuide™ from OMRON Healthcare Named to TIME’s List of the 100 Best Inventions of 2019
TIME recognizes HeartGuide™, the first wearable blood pressure monitor, as one of the groundbreaking inventions that are changing the way we live, work, play and think about what’s possible LAKE FOREST, Ill., Nov. 26, 2019 /PRNewswire/ — OMRON Healthcare, Inc., the global leader in personal heart health and wellness technology, is recognized in […]
InspireMD Reports Updated Positive CGuard™ EPS Data Presented at VEITH 2019
CGuard™ EPS clinical data featured as a prominent discussion point in multiple key presentations Data from investigator-initiated multicenter, 729-patient IRONGUARD 2 study suggests that the use of CGuard™ EPS in routine clinical practice is associated with no major periprocedural, 30-day or one-year neurological complications TEL AVIV, Israel, Nov. 26, 2019 […]
BioSig Technologies Signs Three New Licensing Agreements with Mayo Clinic
Westport, CT, Nov. 26, 2019 (GLOBE NEWSWIRE) — ·New areas of collaboration identified between Mayo Clinic and BioSig ·Focus on previously untapped arrhythmia treatments ·Additional development areas covering novel therapies for autonomic nervous system disease BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a […]
Neovasc Reducer™ Featured In FOCUS Magazine
VANCOUVER, CA, and BERLIN, DE, Nov. 26, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that […]
Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca
Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction The collaboration aims to provide a unique solution for […]



